Ablynx NV has secured a licensing deal with AbbVie Inc for its antibody-derived therapeutic protein ALX-0061 to treat inflammatory diseases. The product targets the interleukin-6 receptor and is in Phase 2 for rheumatoid arthritis and systemic lupus erythematosus (SLE).
